471 related articles for article (PubMed ID: 15474365)
21. Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons.
Ostenfeld T; Tai YT; Martin P; Déglon N; Aebischer P; Svendsen CN
J Neurosci Res; 2002 Sep; 69(6):955-65. PubMed ID: 12205689
[TBL] [Abstract][Full Text] [Related]
22. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
Lo Bianco C; Schneider BL; Bauer M; Sajadi A; Brice A; Iwatsubo T; Aebischer P
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17510-5. PubMed ID: 15576511
[TBL] [Abstract][Full Text] [Related]
23. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.
Xu J; Kao SY; Lee FJ; Song W; Jin LW; Yankner BA
Nat Med; 2002 Jun; 8(6):600-6. PubMed ID: 12042811
[TBL] [Abstract][Full Text] [Related]
24. BDNF is induced by wild-type alpha-synuclein but not by the two mutants, A30P or A53T, in glioma cell line.
Kohno R; Sawada H; Kawamoto Y; Uemura K; Shibasaki H; Shimohama S
Biochem Biophys Res Commun; 2004 May; 318(1):113-8. PubMed ID: 15110760
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of lentiviral vector-mediated overexpression of nerve growth factor and glial cell line-derived neurotrophic factor on regenerating sensory and motor axons in the transected peripheral nerve.
Tannemaat MR; Eggers R; Hendriks WT; de Ruiter GC; van Heerikhuize JJ; Pool CW; Malessy MJ; Boer GJ; Verhaagen J
Eur J Neurosci; 2008 Oct; 28(8):1467-79. PubMed ID: 18973572
[TBL] [Abstract][Full Text] [Related]
26. Synucleins and their relationship to Parkinson's disease.
von Bohlen Und Halbach O
Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
[TBL] [Abstract][Full Text] [Related]
27. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes.
Popovic N; Maingay M; Kirik D; Brundin P
Exp Neurol; 2005 May; 193(1):65-74. PubMed ID: 15817265
[TBL] [Abstract][Full Text] [Related]
28. Viral vectors, animal models and new therapies for Parkinson's disease.
Schneider B; Zufferey R; Aebischer P
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S169-71. PubMed ID: 18585946
[TBL] [Abstract][Full Text] [Related]
29. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.
Winkler C; Georgievska B; Carlsson T; Lacar B; Kirik D
Neuroscience; 2006 Aug; 141(1):521-31. PubMed ID: 16697115
[TBL] [Abstract][Full Text] [Related]
30. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
[TBL] [Abstract][Full Text] [Related]
31. Mutation analysis of the glial cell line-derived neurotrophic factor gene in Parkinson's disease.
Wartiovaara K; Hytönen M; Vuori M; Paulin L; Rinne J; Sariola H
Exp Neurol; 1998 Aug; 152(2):307-9. PubMed ID: 9710530
[TBL] [Abstract][Full Text] [Related]
32. Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease.
Do Thi NA; Saillour P; Ferrero L; Dedieu JF; Mallet J; Paunio T
Gene Ther; 2004 May; 11(9):746-56. PubMed ID: 14724667
[TBL] [Abstract][Full Text] [Related]
33. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Chu Y; Kordower JH
Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
[TBL] [Abstract][Full Text] [Related]
34. An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model.
Hashimoto M; Rockenstein E; Mante M; Crews L; Bar-On P; Gage FH; Marr R; Masliah E
Gene Ther; 2004 Dec; 11(23):1713-23. PubMed ID: 15483670
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of growth/differentiation factor 5 and glial cell line-derived neurotrophic factor on dopaminergic neurons and astroglia in cultures of embryonic rat midbrain.
Wood TK; McDermott KW; Sullivan AM
J Neurosci Res; 2005 Jun; 80(6):759-66. PubMed ID: 15880784
[TBL] [Abstract][Full Text] [Related]
36. Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease.
Ebert AD; Beres AJ; Barber AE; Svendsen CN
Exp Neurol; 2008 Jan; 209(1):213-23. PubMed ID: 18061591
[TBL] [Abstract][Full Text] [Related]
37. Protection of dopaminergic neurons by electroconvulsive shock in an animal model of Parkinson's disease.
Anastasia A; de Erausquin GA; Wojnacki J; Mascó DH
J Neurochem; 2007 Nov; 103(4):1542-52. PubMed ID: 17854351
[TBL] [Abstract][Full Text] [Related]
38. Glial cell line-derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson's disease.
Lapchak PA; Gash DM; Jiao S; Miller PJ; Hilt D
Exp Neurol; 1997 Mar; 144(1):29-34. PubMed ID: 9126148
[TBL] [Abstract][Full Text] [Related]
39. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
Fornai F; Lenzi P; Ferrucci M; Lazzeri G; di Poggio AB; Natale G; Busceti CL; Biagioni F; Giusiani M; Ruggieri S; Paparelli A
Brain Res Bull; 2005 May; 65(5):405-13. PubMed ID: 15833595
[TBL] [Abstract][Full Text] [Related]
40. Adenoviral gene transfer of BDNF and GDNF synergistically prevent motoneuron loss in the nucleus ambiguus.
Moro K; Shiotani A; Watabe K; Takeda Y; Saito K; Mori Y; Ogawa K
Brain Res; 2006 Mar; 1076(1):1-8. PubMed ID: 16473328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
